accountCompany's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD). Improvements in the Unified Parkinson's Disease Rating Scale (UPDRS) at 12 months for the randomized,...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Neurologix Presents One-Year Follow-Up Data From Phase 2 Study Of NLX-P101 In Parkinson's Disease At International Neuromodulation Society 10th World Congress
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account